IGC Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IGC Pharma, Inc. (IGC) on April 14, 2026, reporting events occurring on April 10, 2026. The filing details the entry into material definitive agreements involving the issuance of convertible promissory notes to raise capital for general working capital purposes.
Key Financial Metrics and Debt Obligations
The filing discloses the creation of two new direct financial obligations:
- FirstFire Global Opportunities Fund, LLC Note: Principal amount of $346,910 (including a $39,910 original issue discount). Purchase price paid was $307,000. Maturity date is April 10, 2027.
- Vanquish Funding Group Inc. (VFG) Note: Principal amount of $238,050 (including a $31,050 original issue discount). Purchase price paid was $207,000. Maturity date is March 30, 2027.
- Total Principal Raised: $584,960.
- Total Cash Proceeds: $514,000.
- Interest Rate: 12% per annum for both notes.
The filing text does not provide current revenue, profit, cash flow, or margin data, as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Terms
Both notes contain conversion features triggered solely upon an Event of Default. Key terms include:
- Conversion Price: 75% of the lowest trading price of the Common Stock during the 10 trading days immediately preceding the conversion date.
- Beneficial Ownership Limit: Holders cannot convert if it would result in beneficial ownership exceeding 4.99% of outstanding shares. This limit cannot be waived.
- Conversion Cap: The Company cannot issue shares upon conversion exceeding 19.99% of outstanding shares without shareholder approval.
- Prepayment: The Company may prepay either note in full at any time with prior written notice.
Outlook, Risks, and Contingencies
Management intends to use the proceeds for general working capital. The primary risks associated with these agreements include:
- Dilution Risk: In the event of a default, the conversion price (75% of the lowest trading price) could result in significant dilution to existing shareholders.
- Liquidity Pressure: The Company must service 12% interest on these notes or risk default and potential conversion.
- Regulatory Constraints: Issuance of shares beyond the 19.99% cap requires shareholder approval under NYSE American rules.
Investor Verification Checklist
- Verify the current cash position of IGC Pharma to assess the ability to service the new $584,960 principal debt and 12% interest.
- Review the Company's recent stock price volatility to understand the potential dilution impact if the 75% conversion discount is triggered.
- Confirm whether the Company has existing debt covenants that might be impacted by these new obligations.
- Monitor for any future filings regarding shareholder approval if the conversion cap is approached.